Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Consistency, Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults greater than and equal to 50 Years of Age

Next Previous
Trial Profile

Consistency, Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults greater than and equal to 50 Years of Age

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 137173A (Primary)
  • Indications Herpes zoster
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 16 Jun 2016 Status changed from active, no longer recruiting to completed.
  • 13 Jun 2016 This trial is Completed in Belgium, according to the European Clinical Trials Database.
  • 17 Jun 2015 Planned End Date changed from 1 Apr 2016 to 1 May 2016 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top